利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.025 秒)

    Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
    1.
    发明授权
    Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates 有权
    双功能间苯二酚，间苯二酚和二硫代间苯二酚衍生物金属螯合物

    公开(公告)号：US08119103B2

    公开(公告)日：2012-02-21

    申请号：US12280370

    申请日：2007-02-20

    申请人： Dennis A. Moore

    发明人： Dennis A. Moore

    IPC分类号： A61K49/00

    CPC分类号： A61K51/088 ,  A61K47/551 ,  A61K49/0002 ,  A61K49/085 ,  A61K49/10 ,  A61K49/14 ,  A61K51/0474

    摘要： The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and metal coordinating moiety comprising a resorcinol, thioresorcinol, or dithioresorcinol derivative through which the metal coordinating moiety is bonded to the linker.

    摘要翻译： 本发明涉及用作金属药物诊断或治疗剂的金属螯合缀合物。 具体地，本发明的缀合物包括一种或多种载体，接头和包含间苯二酚，间苯二酚或二硫代间苯二酚衍生物的金属配位部分，金属配位部分通过其连接到连接体上。

    Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates
    2.
    发明申请
    Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates 有权
    双功能间苯二酚，间苯二酚和二硫代间苯二酚衍生金属螯合缀合物

    公开(公告)号：US20090082324A1

    公开(公告)日：2009-03-26

    申请号：US12280370

    申请日：2007-02-20

    申请人： Dennis A. Moore

    发明人： Dennis A. Moore

    IPC分类号： A61K31/555 ,  C07D257/02 ,  A61P35/00

    CPC分类号： A61K51/088 ,  A61K47/551 ,  A61K49/0002 ,  A61K49/085 ,  A61K49/10 ,  A61K49/14 ,  A61K51/0474

    摘要： The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and metal coordinating moiety comprising a resorcinol, thioresorcinol, or dithioresorcinol derivative through which the metal coordinating moiety is bonded to the linker.

    摘要翻译： 本发明涉及用作金属药物诊断或治疗剂的金属螯合缀合物。 具体地，本发明的缀合物包括一种或多种载体，接头和包含间苯二酚，间苯二酚或二硫代间苯二酚衍生物的金属配位部分，金属配位部分通过其连接到连接体上。

    Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function
    3.
    发明申请
    Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function 有权
    荧光吡嗪衍生物及其在肾功能评估中的应用方法

    公开(公告)号：US20090010851A1

    公开(公告)日：2009-01-08

    申请号：US11721186

    申请日：2005-12-22

    申请人： Raghavan Rajagopalan ,  Richard B. Dorshow ,  William L. Neumann ,  Dennis A. Moore

    发明人： Raghavan Rajagopalan ,  Richard B. Dorshow ,  William L. Neumann ,  Dennis A. Moore

    IPC分类号： A61K49/00

    CPC分类号： C07D241/28 ,  A61K31/4965 ,  A61K49/0004 ,  A61K49/0021 ,  A61K49/0052 ,  C07D241/20 ,  C07D241/26

    摘要： The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 of Formulas I and II may be characterized as electron withdrawing groups, while Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.

    摘要翻译： 本发明涉及吡嗪衍生物，例如由式I和II表示的衍生物。 式I和II的X 1至X 4可以表征为吸电子基团，而式I和II的Y1至Y4可以表征为给电子基团。 本发明的吡嗪衍生物可用于评估器官（例如肾）功能。 在具体实例中，有效量的能够被再次清除的吡嗪衍生物可以被施用到患者体内。 吡嗪衍生物可以具有一个或两个吸收和发射至少约400nm的光谱能量（例如可见光和/或红外光）。 身体中的至少一些衍生物可能暴露于光谱能量，反过来，光谱能量可能来自衍生物。 这种发出的光谱能量可以被检测并用于确定患者的肾功能。

    Methods and compositions for magnetic resonance imaging
    6.
    发明授权
    Methods and compositions for magnetic resonance imaging 失效
    磁共振成像的方法和组成

    公开(公告)号：US5330742A

    公开(公告)日：1994-07-19

    申请号：US862865

    申请日：1992-04-03

    申请人： Edward A. Deutsch ,  Dennis A. Moore

    发明人： Edward A. Deutsch ,  Dennis A. Moore

    IPC分类号： A61K47/30 ,  A61K49/00 ,  A61K49/04 ,  A61K49/06 ,  A61K49/18 ,  C01B25/32 ,  C07F13/00 ,  G01N31/00

    CPC分类号： A61K49/1818 ,  A61K49/04 ,  A61K49/0433 ,  A61K49/06 ,  A61K49/1887 ,  Y10S436/806 ,  Y10S514/836 ,  Y10T436/24

    摘要： Methods and diagnostic compositions are disclosed for enhancing magnetic resonance imaging which utilize a paramagnetic metal cluster. Magnetic resonance contrast media containing Z+[Mn.sub.12 X.sub.12 (OYR).sub.16 (L).sub.4 ], where OYR is an oxyacid such as benzoic acid, acetic acid, methyl sulphonic acid, methyl phosphonic acid; L is a neutral donor such as water, alcohol, pyridine, or other amines; X is a chalcogen, such as O or S; and Z is a pharmaceutically acceptable counterion are disclosed. Z may also be a paramagnetic counter ion, such as a high spin metal cluster. The paramagnetic cluster may optionally be complexed or conjugated to a carrier compound capable of altering the paramagnetic metal cluster's biodistribution, increasing its selectivity of tumor localization, and amplifying its proton relaxivity.

    摘要翻译： 公开了用于增强利用顺磁金属簇的磁共振成像的方法和诊断组合物。 含有Z + [Mn12X12（OYR）16（L）4]的磁共振造影剂，其中OYR是含氧酸，例如苯甲酸，乙酸，甲基磺酸，甲基膦酸; L是中性给体，例如水，醇，吡啶或其它胺; X是硫属元素，如O或S; 并且Z是药学上可接受的抗衡离子。 Z也可以是顺磁抗衡离子，例如高自旋金属簇。 顺磁簇可以任选地复合或缀合到能够改变顺磁性金属簇的生物分布，增加其对肿瘤定位的选择性和扩增其质子弛豫性的载体化合物。

    Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent
    8.
    发明授权
    Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent 有权
    与己糖载体连接的金属螯合物用作金属药物诊断或治疗剂

    公开(公告)号：US08858916B2

    公开(公告)日：2014-10-14

    申请号：US13120537

    申请日：2009-09-25

    申请人： Dennis A. Moore

    发明人： Dennis A. Moore

    IPC分类号： A61K49/10 ,  A61K51/04 ,  A61K49/00

    CPC分类号： C07H15/26 ,  A61K49/0002 ,  A61K51/048 ,  A61K51/0482 ,  A61K51/0491 ,  C07H15/12

    摘要： A compound comprising a metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent is provided. The compound is suitable for imaging by single-photon emission computed tomography, computer assisted tomography, magnetic resonance spectroscopy, magnetic resonance imaging, positron emission tomography, fluorescence imaging or x-ray.

    摘要翻译： 提供了包含与己糖载体连接的金属螯合物用作金属药物诊断或治疗剂的化合物。 该化合物适用于通过单光子发射计算机断层扫描，计算机辅助断层扫描，磁共振光谱，磁共振成像，正电子发射断层扫描，荧光成像或X射线成像。

    Apparatus and Method to Determine Contrast Media Injection Parameters to Control Signal Intensity During Magnetic Resonance Angiography
    9.
    发明申请
    Apparatus and Method to Determine Contrast Media Injection Parameters to Control Signal Intensity During Magnetic Resonance Angiography 有权
    在磁共振血管造影术中确定对比介质注射参数以控制信号强度的装置和方法

    公开(公告)号：US20130345548A1

    公开(公告)日：2013-12-26

    申请号：US14003893

    申请日：2012-03-14

    申请人： Michael R. Hynes ,  Dennis A. Moore ,  William J. Neubert

    发明人： Michael R. Hynes ,  Dennis A. Moore ,  William J. Neubert

    IPC分类号： A61M5/00 ,  A61B5/055

    CPC分类号： A61M5/007 ,  A61B5/055 ,  A61M5/1452 ,  A61M5/14546 ,  A61M2005/14553

    摘要： Injection systems and related methods including an injection device, an operator interface, and modules to determine operational parameters during an MRA imaging procedure. Such parameters may be used to optimize and/or maximize signal intensity during an MRA imaging procedure. The injection system may include a target in-bloodstream contrast agent concentration determination module that determines a target in-bloodstream contrast agent concentration at least partially based on contrast agent type and MRA imager parameters. The injection system may include a contrast agent injection rate determination module that determines a contrast agent injection rate at least partially based on the target in-bloodstream contrast agent concentration, an initial contrast agent concentration, and a cardiac output rate of a patient to be imaged. The injection system may include a diluent injection rate determination module that determines a diluent injection rate at least partially based on the contrast agent injection rate.

    摘要翻译： 注射系统和相关方法，包括注射装置，操作者界面和用于在MRA成像过程期间确定操作参数的模块。 这样的参数可用于在MRA成像过程期间优化和/或最大化信号强度。 注射系统可以包括目标血液中造影剂浓度确定模块，其至少部分地基于造影剂类型和MRA成像器参数来确定靶内血流造影剂浓度。 注射系统可以包括造影剂注射速率确定模块，其至少部分地基于目标血流造影剂浓度，初始造影剂浓度和待成像的患者的心输出量来确定造影剂注射速率 。 注射系统可以包括稀释剂注射速率确定模块，其至少部分地基于造影剂注射速率确定稀释剂注射速率。